Brainstorm Cell Therapeutics Inc. · OTC:BCLI
Brainstorm Cell Therapeutics — Investor Day (2018)
6 slides from Brainstorm Cell Therapeutics's investor day presentation, 2018
Slide 1: BrainStorm Cell Therapeutics Cell & Gene Therapy Investor Day
בס"ד BrainStorm Cell Prepared Therapeutics NASDAQ: BCLI Chaim Lebovits CEO Cell & Gene Therapy Investor Day
Slide 2: Forward Looking Statement
בס"ד Forward Looking Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implie
Slide 3: 2017-2018 Company Progress
בס"ד 2017-2018 Company Progress Manufacturing Technology Strong Clinical and Basic Science Excellence • Phase 3 ALS study enrolling at 6 US • Advanced autologous cell sites therapy platform • Broad CNS preclinical pipeline • NurOwn Cryopreservation • 2 AAN platform presentations April 2018 Non-Dil
Slide 4: NurOwn ALS Development
בס"ד NurOwn® ALS Development Phase 2 Phase 3 NurOwn Phase 1/2a Randomized Randomized 2007 Preclinical 2010 Open Label 2014 3:1 2017+ 1:1 Development Single Dose 3 US sites 6 US sites Single Dose 3 Doses Enhanced NTF Production MSC-NTF Cells Responder Analysis ≥ 1.5 point/month improvement GDNF BDN
Slide 5: Company Leadership Capabilities Strengthened
בס"ד Company Leadership Capabilities Strengthened Board of Directors- recent Management Team Scientific Advisory Board additions • Chaim Lebovits, CEO • Arturo Arraya MA, BS, MBA, • Jerold Chun MD PhD, • Ralph Kern MD, COO and CMO formerly Vice President and Neuroscientist and Professor at • Uri Y
Slide 6: Thank You
בס"ד BrainStorm Cell Therapeutics NASDAQ: BCLI Thank You